Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

23.51 -1.88 (-7.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
What's Driving the Market Sentiment Around Moderna?
 
Via Benzinga
Pfizer In Spotlight As FDA Reportedly Mulls Withdrawing Authorization For COVID-19 Vaccine For Kids Under 5: Retail Says Stock Is Undervalued
According to a Bloomberg report, Pfizer has requested that the approval stay in place through the coming fall season. 
Via Stocktwits
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern on board to fill in gaps. 
Via Benzinga
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight. 
Via Benzinga
Moderna's Earnings: A Preview
 
Via Benzinga
The 3 Things That Matter for Moderna Now
The company is still trying to prove that it isn't just a pandemic play. 
Via The Motley Fool
3 Cash-Burning Stocks That Fall Short
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable. 
Via StockStory
RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies'
The Department of Health and Human Services will cancel 22 vaccine development projects totaling $500 million. 
Via Benzinga
1 S&P 500 Stock to Consider Right Now and 2 Facing Headwinds
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca
Via Stocktwits
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio?
Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts. 
Via Benzinga
Discover which S&P500 stocks are making waves on Friday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session. 
Via Chartmill
Stay informed with the top movers within the S&P500 index on Friday.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session. 
Via Chartmill
Why Moderna (MRNA) Stock Is Trading Lower Today
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 7.1% in the afternoon session after the company trimmed the upper end of its 2025 revenue forecast, citing a delay in vaccine shipments. The... 
Via StockStory
Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector
Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna reported disappointing Q2 results. 
Via Benzinga
Which S&P500 stocks are gapping on Friday?
Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Moderna CEO Attributes Full-Year Revenue Guidance Reduction To Timing Of Shipments: Retail Pins Hopes On Pipeline After Q2 Beat
The vaccine maker lowered its full-year revenue guidance to a range of $1.5 billion to $2.2 billion, reflecting a $300 million reduction at the high end of the range. 
Via Stocktwits
Topics Artificial Intelligence
Moderna's Key Patent Win Overshadowed By Gloomy Outlook
Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of its global workforce. 
Via Benzinga
Topics Intellectual Property
Top S&P500 movers in Friday's pre-market session
Curious about the S&P500 stocks that are showing activity before the opening bell on Friday? 
Via Chartmill
Moderna (NASDAQ:MRNA) Exceeds Q2 Expectations But Stock Drops
Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales fell by 41.1% year on year to $142 million. On the other hand, the... 
Via StockStory
Moderna Stock Falls Again Amid Lowered Guidance, Job Cuts
The biotech reported a smaller-than-expected Q2 loss and revenue decline. 
Via Investor's Business Daily
Topics Artificial Intelligence
Dow Futures Decline As Trump Unleashes Tariffs Globally: AAPL, AMZN, COIN, RDDT, CVX, XOM Among Stocks To Watch
While Dow Jones futures were down 0.94% at the time of writing, the S&P 500 futures fell 0.95%. 
Via Stocktwits
Topics ETFs Government Stocks
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
Via ACCESS Newswire
UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
Via ACCESS Newswire
Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
 
Via Benzinga
Earnings Scheduled For August 1, 2025
 
Via Benzinga
Moderna Announces 10% Layoffs Ahead Of Q2 Report: Retail Now Eyes ‘Good Enough’ Earnings
CEO Stéphane Bancel said in a note to employees on Thursday that the move is part of the company’s commitment to reduce annual operating expenses by about $1.5 billion by 2027. 
Via Stocktwits
Topics Artificial Intelligence Supply Chain Workforce
Moderna Announces 10% Workforce Cut Amid Declining COVID-19 Vaccine Sales, Regulatory Hurdles
Moderna Inc. (NASDAQ: MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty. 
Via Benzinga
Moderna Earnings: What To Look For From MRNA
Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday before the bell. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence Government World Trade
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.